PMID- 21353102
OWN - NLM
STAT- MEDLINE
DCOM- 20110624
LR  - 20181201
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 32
IP  - 14
DP  - 2010 Dec
TI  - Systematic review and meta-analysis of the efficacy and tolerability of nicotine 
      preparations in active ulcerative colitis.
PG  - 2304-15
LID - 10.1016/j.clinthera.2011.01.004 [doi]
AB  - BACKGROUND: Findings from clinical studies of the efficacy and tolerability of 
      nicotine preparations in maintaining remission of ulcerative colitis (UC) have 
      been inconsistent. OBJECTIVES: This systematic review and meta-analysis aimed to 
      assess the efficacy and tolerability of nicotine preparations in inducing 
      remission in UC. METHODS: A literature search (1966 August 2010) of Scopus 
      (EMBASE), PubMed, Web of Science, and the Cochrane Central Register of Controlled 
      Trials was conducted for clinical trials that investigated the efficacy and/or 
      tolerability (any adverse events [AEs] and withdrawals due to AEs) of any 
      nicotine preparation for the induction of remission in UC. RESULTS: The 
      electronic searches yielded 788 items. Of these, 3 placebo-controlled trials 
      representing 233 patients with UC and 2 randomized controlled trials that 
      compared nicotine to corticosteroids in 81 patients with UC were included in 
      meta-analysis. The summary relative risks (RRs) (95% CI) in comparing nicotine to 
      placebo were 1.40 (0.63-3.12) (P = NS) for clinical remission, 1.95 (1.38-2.78) 
      (P < 0.001) for AEs, and 3.44 (0.71-16.71) (P = NS) for withdrawal due to AEs. 
      The summary RRs in comparing nicotine to corticosteroids 
      (prednisolone/prednisone) were 0.74 (0.5-1.09) (P = NS) for clinical remission in 
      2 trials and 2.28 (0.76-6.83) (P = NS) for withdrawal due to AEs. CONCLUSION: The 
      findings from this meta-analysis do not support the efficacy or tolerability of 
      nicotine preparations in inducing remission in UC.
CI  - Copyright (c) 2010. Published by EM Inc USA.
FAU - Nikfar, Shekoufeh
AU  - Nikfar S
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Ehteshami-Ashar, Solmaz
AU  - Ehteshami-Ashar S
FAU - Rahimi, Roja
AU  - Rahimi R
FAU - Abdollahi, Mohammad
AU  - Abdollahi M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 6M3C89ZY6R (Nicotine)
SB  - IM
MH  - Adrenal Cortex Hormones/administration & dosage/adverse effects/*therapeutic use
MH  - Anti-Inflammatory Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Colitis, Ulcerative/*drug therapy/epidemiology
MH  - Humans
MH  - Nicotine/administration & dosage/adverse effects/*therapeutic use
MH  - Remission Induction
MH  - Treatment Outcome
EDAT- 2011/03/01 06:00
MHDA- 2011/06/28 06:00
CRDT- 2011/03/01 06:00
PHST- 2010/10/26 00:00 [accepted]
PHST- 2011/03/01 06:00 [entrez]
PHST- 2011/03/01 06:00 [pubmed]
PHST- 2011/06/28 06:00 [medline]
AID - S0149-2918(11)00005-1 [pii]
AID - 10.1016/j.clinthera.2011.01.004 [doi]
PST - ppublish
SO  - Clin Ther. 2010 Dec;32(14):2304-15. doi: 10.1016/j.clinthera.2011.01.004.